Anticipatory activation of the unfolded protein response by epidermal growth factor is required for immediate early gene expression and cell proliferation

Molecular and Cellular Endocrinology

Volumn 422, Issue , 2016, Pages 31-41

  Yu, Liqun ^a   Andruska, Neal ^a,c   Zheng, Xiaobin ^a   Shapiro, David J ^a,b,c  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c UNIVERSITY OF ILLINOIS   (United States)

Author keywords

Breast cancer; Calcium; Epidermal growth factor (EGF); Gene regulation; Unfolded protein response (UPR)

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 4; ACTIVATING TRANSCRIPTION FACTOR 6; ACTIVATING TRANSCRIPTION FACTOR 6ALPHA; CALCIUM CHANNEL; CALCIUM ION; EARLY GROWTH RESPONSE FACTOR 1; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GLUCOSE REGULATED PROTEIN 78; INITIATION FACTOR 2ALPHA; INOSITOL 1,4,5 TRISPHOSPHATE RECEPTOR; INOSITOL TRISPHOSPHATE; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHOLIPASE C GAMMA; PROTEIN FOS; PROTEIN IRE1; PROTEIN IRE1ALPHA; PROTEIN KINASE B; UNCLASSIFIED DRUG; X BOX BINDING PROTEIN 1; CALCIUM; EGFR PROTEIN, HUMAN;

ARTICLE; ATF4 GENE; BIP GENE; BREAST CANCER CELL LINE; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CELL PROLIFERATION; CONTROLLED STUDY; EGR1 GENE; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVATION; FOS GENE; GENE EXPRESSION; GENE INDUCTION; GENE REPRESSION; HER2 GENE; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; UNFOLDED PROTEIN RESPONSE; UPR GENE; BREAST TUMOR; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; IMMEDIATE EARLY GENE; METABOLISM; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

BREAST NEOPLASMS; CALCIUM; CELL LINE, TUMOR; CELL PROLIFERATION; EPIDERMAL GROWTH FACTOR; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, IMMEDIATE-EARLY; HUMANS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; UNFOLDED PROTEIN RESPONSE;

EID: 84961301489     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2015.11.005     Document Type: Article

References (66)

1. Agell N., Bachs O., Rocamora N., Villalonga P. Modulation of the Ras/Raf/MEK/ERK pathway by Ca 2+, and calmodulin. Cell. Signal. 2002, 14:649-654.
2. Andruska N., Zheng X., Yang Y., Helferich W.G., Shapiro D.J. Anticipatory estrogen activation of the unfolded protein response is linked to cell proliferation and poor survival in estrogen receptor alpha-positive breast cancer. Oncogene 2015, 34:3760-3769.
3. Andruska N.D., Zheng X., Yang X., Mao C., Cherian M.M., Mahapatra L., Helferich W.G., Shapiro D.J. Estrogen receptor α inhibitor activates the unfolded protein response, blocks protein synthesis, and induces tumor regression. Proc. Natl. Acad. Sci. 2015, 112:4737-4742.
4. Auf G., Jabouille A., Guérit S., Pineau R., Delugin M., Bouchecareilh M., Magnin N., Favereaux A., Maitre M., Gaiser T. Inositol-requiring enzyme 1α is a key regulator of angiogenesis and invasion in malignant glioma. Proc. Natl. Acad. Sci. 2010, 107:15553-15558.
5. Baselga J., Arteaga C.L. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2005, 23:2445-2459.
6. Baselga J., Albanell J., Ruiz A., Lluch A., Gascon P., Guillem V., Gonzalez S., Sauleda S., Marimon I., Tabernero J.M., Koehler M.T., Rojo F. Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2005, 23:5323-5333.
7. Bromati C.R., Lellis-Santos C., Yamanaka T.S., Nogueira T.C., Leonelli M., Caperuto L.C., Gorjao R., Leite A.R., Anhe G.F., Bordin S. UPR induces transient burst of apoptosis in islets of early lactating rats through reduced AKT phosphorylation via ATF4/CHOP stimulation of TRB3 expression. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2011, 300:R92-R100.
8. Brown J.M., Wilson W.R. Exploiting tumour hypoxia in cancer treatment. Nat. Rev. Cancer 2004, 4:437-447.
9. Brown J.R., Nigh E., Lee R.J., Ye H., Thompson M.A., Saudou F., Pestell R.G., Greenberg M.E. Fos family members induce cell cycle entry by activating cyclin D1. Mol. Cell. Biol. 1998, 18:5609-5619.
10. Chao T., Byron K., Lee K., Villereal M., Rosner M.R. Activation of MAP kinases by calcium-dependent and calcium-independent pathways. Stimulation by thapsigargin and epidermal growth factor. J. Biol. Chem. 1992, 267:19876-19883.
11. Chen Y., Brandizzi F. IRE1: ER stress sensor and cell fate executor. Trends Cell Biol. 2013, 23:547-555.
12. Cherian M.T., Wilson E.M., Shapiro D.J. A competitive inhibitor that reduces recruitment of androgen receptor to androgen-responsive genes. J. Biol. Chem. 2012, 287:23368-23380.
13. Clarke R., Cook K.L. Unfolding the role of stress response signaling in endocrine resistant breast cancers. Front. Oncol. 2015, 5.
14. Clarke R., Tyson J.J., Dixon J.M. Endocrine resistance in breast cancer-an overview and update. Mol. Cell. Endocrinol. 2015, 418(3):220-234.
15. Cook K.L., Shajahan A.N., Wärri A., Jin L., Hilakivi-Clarke L.A., Clarke R. Glucose-regulated protein 78 controls cross-talk between apoptosis and autophagy to determine antiestrogen responsiveness. Cancer Res. 2012, 72:3337-3349.
16. Crozat A., Åman P., Mandahl N., Ron D. Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma. Nature 1993, 363:640-644.
17. Dent R., Trudeau M., Pritchard K.I., Hanna W.M., Kahn H.K., Sawka C.A., Lickley L.A., Rawlinson E., Sun P., Narod S.A. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2007, 13:4429-4434.
18. Dickler M.N., Cobleigh M.A., Miller K.D., Klein P.M., Winer E.P. Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer. Breast cancer Res. Treat. 2009, 115:115-121.
19. Ding L., Yan J., Zhu J., Zhong H., Lu Q., Wang Z., Huang C., Ye Q. Ligand-independent activation of estrogen receptor α by XBP-1. Nucleic Acids Res. 2003, 31:5266-5274.
20. Dittmar T., Husemann A., Schewe Y., Nofer J.R., Niggemann B., Zanker K.S., Brandt B.H. Induction of cancer cell migration by epidermal growth factor is initiated by specific phosphorylation of tyrosine 1248 of c-erbB-2 receptor via EGFR. FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 2002, 16:1823-1825.
21. Dong D., Ni M., Li J., Xiong S., Ye W., Virrey J.J., Mao C., Ye R., Wang M., Pen L. Critical role of the stress chaperone GRP78/BiP in tumor proliferation, survival, and tumor angiogenesis in transgene-induced mammary tumor development. Cancer Res. 2008, 68:498-505.
22. Dong D.-J., Jing Y.-P., Liu W., Wang J.-X., Zhao X.-F. The steroid hormone 20-hydroxyecdysone upregulates Ste-20 family serine/threonine kinase Hippo to induce programmed cell death. J. Biol. Chem 2015, jbc. M115. 643783.
23. Fang Y., Yan J., Ding L., Liu Y., Zhu J., Huang C., Zhao H., Lu Q., Zhang X., Yang X. XBP-1 increases ERα transcriptional activity through regulation of large-scale chromatin unfolding. Biochem. Biophys. Res. Commun. 2004, 323:269-274.
24. Gomez B.P., Riggins R.B., Shajahan A.N., Klimach U., Wang A., Crawford A.C., Zhu Y., Zwart A., Wang M., Clarke R. Human X-box binding protein-1 confers both estrogen independence and antiestrogen resistance in breast cancer cell lines. FASEB J. 2007, 21:4013-4027.
25. Gu Z., Lee R.Y., Skaar T.C., Bouker K.B., Welch J.N., Lu J., Liu A., Zhu Y., Davis N., Leonessa F. Association of interferon regulatory factor-1, nucleophosmin, nuclear factor-κB, and cyclic AMP response element binding with acquired resistance to Faslodex (ICI 182,780). Cancer Res. 2002, 62:3428-3437.
26. Herbst R.S., Langer C.J. Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers. Seminars in Oncology 2002, Elsevier.
27. Hernandez C.C., Zaika O., Tolstykh G.P., Shapiro M.S. Regulation of neural KCNQ channels: signalling pathways, structural motifs and functional implications. J. Physiol. 2008, 586:1811-1821.
28. Holbro T., Civenni G., Hynes N.E. The ErbB receptors and their role in cancer progression. Exp. Cell Res. 2003, 284:99-110.
29. Jenner R.G., Maillard K., Cattini N., Weiss R.A., Boshoff C., Wooster R., Kellam P. Kaposi's sarcoma-associated herpesvirus-infected primary effusion lymphoma has a plasma cell gene expression profile. Proc. Natl. Acad. Sci. 2003, 100:10399-10404.
30. Karali E., Bellou S., Stellas D., Klinakis A., Murphy C., Fotsis T. VEGF signals through ATF6 and PERK to promote endothelial cell survival and angiogenesis in the absence of ER stress. Mol. Cell 2014, 54:559-572.
31. Lee A.-H., Iwakoshi N.N., Glimcher L.H. XBP-1 regulates a subset of endoplasmic reticulum resident chaperone genes in the unfolded protein response. Mol. Cell. Biol. 2003, 23:7448-7459.
32. Lee A.-H., Iwakoshi N.N., Anderson K.C., Glimcher L.H. Proteasome inhibitors disrupt the unfolded protein response in myeloma cells. Proc. Natl. Acad. Sci. 2003, 100:9946-9951.
33. Lee E., Nichols P., Spicer D., Groshen S., Mimi C.Y., Lee A.S. GRP78 as a novel predictor of responsiveness to chemotherapy in breast cancer. Cancer Res. 2006, 66:7849-7853.
34. Lee M.J., Ye A.S., Gardino A.K., Heijink A.M., Sorger P.K., MacBeath G., Yaffe M.B. Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks. Cell 2012, 149:780-794.
35. Lee A.S. GRP78 induction in cancer: therapeutic and prognostic implications. Cancer Res. 2007, 67:3496-3499.
36. Lee A.S. Glucose-regulated proteins in cancer: molecular mechanisms and therapeutic potential. Nat. Rev. Cancer 2014, 14:263-276.
37. Lin H., Hsieh F., Song H., Lin J. Elevated phosphorylation and activation of PDK-1/AKT pathway in human breast cancer. Br. J. Cancer 2005, 93:1372-1381.
38. Liu W., Cai M.-J., Zheng C.-C., Wang J.-X., Zhao X.-F. Phospholipase Cγ1 connects the cell membrane pathway to the nuclear receptor pathway in insect steroid hormone signaling. J. Biol. Chem. 2014, 289:13026-13041.
39. Luo B., Lee A.S. The critical roles of endoplasmic reticulum chaperones and unfolded protein response in tumorigenesis and anticancer therapies. Oncogene 2013, 32:805-818.
40. Luo S., Mao C., Lee B., Lee A.S. GRP78/BiP is required for cell proliferation and protecting the inner cell mass from apoptosis during early mouse embryonic development. Mol. Cell. Biol. 2006, 26:5688-5697.
41. Ma Y., Hendershot L.M. The role of the unfolded protein response in tumour development: friend or foe?. Nat. Rev. Cancer 2004, 4:966-977.
42. Margolis B., Bellot F., Honegger A., Ullrich A., Schlessinger J., Zilberstein A. Tyrosine kinase activity is essential for the association of phospholipase C-gamma with the epidermal growth factor receptor. Mol. Cell. Biol. 1990, 10:435-441.
43. Masuda H., Zhang D., Bartholomeusz C., Doihara H., Hortobagyi G.N., Ueno N.T. Role of epidermal growth factor receptor in breast cancer. Breast Cancer Res. Treat. 2012, 136:331-345.
44. Moretti L., Cha Y.I., Niermann K.J., Lu B. Switch between apoptosis and autophagy: radiation-induced endoplasmic reticulum stress?. Cell Cycle 2007, 6:793-798.
45. Murphy L.O., Smith S., Chen R.-H., Fingar D.C., Blenis J. Molecular interpretation of ERK signal duration by immediate early gene products. Nat. Cell Biol. 2002, 4:556-564.
46. Nawrocki S.T., Carew J.S., Dunner K., Boise L.H., Chiao P.J., Huang P., Abbruzzese J.L., McConkey D.J. Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells. Cancer Res. 2005, 65:11510-11519.
47. Novoa I., Zeng H., Harding H.P., Ron D. Feedback inhibition of the unfolded protein response by GADD34-mediated dephosphorylation of eIF2α. J. Cell Biol. 2001, 153:1011-1022.
48. Okada T., Yoshida H., Akazawa R., Negishi M., Mori K. Distinct roles of activating transcription factor 6 (ATF6) and double-stranded RNA-activated protein kinase-like endoplasmic reticulum kinase (PERK) in transcription during the mammalian unfolded protein response. Biochem. J. 2002, 366:585-594.
49. Okada T., Yoshida H., Akazawa R., Negishi M., Mori K. Distinct roles of activating transcription factor 6 (ATF6) and double-stranded RNA-activated protein kinase-like endoplasmic reticulum kinase (PERK) in transcription during the mammalian unfolded protein response. Biochem. J. 2002, 366:585-594.
50. Pattarozzi A., Gatti M., Barbieri F., Würth R., Porcile C., Lunardi G., Ratto A., Favoni R., Bajetto A., Ferrari A. 17β-Estradiol promotes breast cancer cell proliferation-inducing stromal cell-derived factor-1-mediated epidermal growth factor receptor transactivation: reversal by gefitinib pretreatment. Mol. Pharmacol. 2008, 73:191-202.
51. Prabhu A., Sarcar B., Kahali S., Shan Y., Chinnaiyan P. Targeting the unfolded protein response in glioblastoma cells with the fusion protein EGF-SubA. PloS One 2012, 7:e52265.
52. Reis-Filho J.S., Pinheiro C., Lambros M.B., Milanezi F., Carvalho S., Savage K., Simpson P.T., Jones C., Swift S., Mackay A., Reis R.M., Hornick J.L., Pereira E.M., Baltazar F., Fletcher C.D., Ashworth A., Lakhani S.R., Schmitt F.C. EGFR amplification and lack of activating mutations in metaplastic breast carcinomas. J. Pathol. 2006, 209:445-453.
53. Ron D., Walter P. Signal integration in the endoplasmic reticulum unfolded protein response. Nat. Rev. Mol. Cell Biol. 2007, 8:519-529.
54. Ron D., Walter P. Signal integration in the endoplasmic reticulum unfolded protein response. Nat. Rev. Mol. Cell Biol. 2007, 8:519-529.
55. Ruggero D. Translational control in cancer etiology. Cold Spring Harb. Perspect. Biol. 2013, 5. a012336.
56. Sahin Ö., Löbke C., Korf U., Appelhans H., Sültmann H., Poustka A., Wiemann S., Arlt D. Combinatorial RNAi for quantitative protein network analysis. Proc. Natl. Acad. Sci. 2007, 104:6579-6584.
57. Sainsbury J.R., Farndon J.R., Needham G.K., Malcolm A.J., Harris A.L. Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet 1987, 1:1398-1402.
58. Salomon D.S., Brandt R., Ciardiello F., Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol./Hematol. 1995, 19:183-232.
59. Saxena R., Dwivedi A. ErbB family receptor inhibitors as therapeutic agents in breast cancer: current status and future clinical perspective. Med. Res. Rev. 2012, 32:166-215.
60. Schmitt J.M., Wayman G.A., Nozaki N., Soderling T.R. Calcium activation of ERK mediated by calmodulin kinase I. J. Biol. Chem. 2004, 279:24064-24072.
61. Shuda M., Kondoh N., Imazeki N., Tanaka K., Okada T., Mori K., Hada A., Arai M., Wakatsuki T., Matsubara O. Activation of the ATF6, XBP1 and grp78 genes in human hepatocellular carcinoma: a possible involvement of the ER stress pathway in hepatocarcinogenesis. J. Hepatol. 2003, 38:605-614.
62. Walter P., Ron D. The unfolded protein response: from stress pathway to homeostatic regulation. Science 2012, 334:1081-1086.
63. Wu J., Rutkowski D.T., Dubois M., Swathirajan J., Saunders T., Wang J., Song B., Yau G.D., Kaufman R.J. ATF6alpha optimizes long-term endoplasmic reticulum function to protect cells from chronic stress. Dev. Cell 2007, 13:351-364.
64. Yarden Y., Pines G. The ERBB network: at last, cancer therapy meets systems biology. Nat. Rev. Cancer 2012, 12:553-563.
65. Zell J.A., Tsang W.Y., Taylor T.H., Mehta R.S., Anton-Culver H. Prognostic impact of human epidermal growth factor-like receptor 2 and hormone receptor status in inflammatory breast cancer (IBC): analysis of 2,014 IBC patient cases from the California Cancer Registry. Breast Cancer Res. BCR 2009, 11:R9.
66. Zwang Y., Oren M., Yarden Y. Consistency test of the cell cycle: roles for p53 and EGR1. Cancer Res. 2012, 72:1051-1054.